Clinical Trial: NCT03567876
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Fondazione Italiana Linfomi - ETS |
| Information Provided By: | Fondazione Italiana Linfomi - ETS |
| Last Update Posted: | 2025-12-08 |
Study Overview
Brief Summary
Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free Survival.
Official Title
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Conditions
Lymphoma, Mantle-Cell
Intervention / Treatment
- Drug: Venetoclax
Other Study ID Numbers
- FIL_V-RBAC
Start Date (Actual)
2018-09-03
Primary Completion Date (Actual)
2021-07-26
Study Completion Date (Actual)
2025-10-15
Enrollment (Actual)
141
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Fondazione Italiana Linfomi - ETS |
| Information Provided By: | Fondazione Italiana Linfomi - ETS |
| Last Update Posted: | 2025-12-08 |
Study Overview
Brief Summary
Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free Survival.
Official Title
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Conditions
Lymphoma, Mantle-Cell
Intervention / Treatment
- Drug: Venetoclax
Other Study ID Numbers
- FIL_V-RBAC
Start Date (Actual)
2018-09-03
Primary Completion Date (Actual)
2021-07-26
Study Completion Date (Actual)
2025-10-15
Enrollment (Actual)
141
Study Type
Interventional
Phase
Phase 2